Dr. Mark Socinski, University of Pittsburgh Medical Center, discusses the factors to consider in defining resectability in stage IIIa lung cancer.
Dr. Mark Socinski, University of Pittsburgh Medical Center, compares the use of chemotherapy to chemo/radiation in the preoperative setting in stage IIIA lung cancer.
Dr. Mark Socinski, University of Pittsburgh Medical Center, describes the primary treatment options for stage IIIA NSCLC, including chemoradiation and surgery, and discusses trial evidence for each approach.
Dr. Mark Socinski, University of Pittsburgh Medical Center, defines the three compartments in stage III (locally advanced) NSCLC, each of which must be treated.
Dr. Mark Socinski, University of Pittsburgh Medical Center, describes the different types of stage III (locally advanced) NSCLC, and states which of these types tend to be resectable.
Guest post by Dr. Cathy Pietanza, a board-certified medical oncologist at Memorial Sloan Kettering Cancer Center in New York. She specializes in cancers that arise in the lungs and cares for a large number of patients with small cell lung cancer (SCLC).
Drs. Leora Horn, Ben Solomon, & Jack West consider the merits of administering immune checkpoint inhibitors concurrently with standard first line chemotherapy or targeted therapy vs. sequential treatment.
Drs. Leora Horn, Ben Solomon, & Jack West consider the merits of administering immune checkpoint inhibitors concurrently with standard first line chemotherapy or targeted therapy vs. sequential treatment.
Dr. Jack West asks the question of whether newer, more active ALK inhibitors such as alectinib should be used as first line therapy rather than for acquired resistance, including introducing the ALEX trial that is trying to answer this question.
Dr. Jack West asks the question of whether newer, more active ALK inhibitors such as alectinib should be used as first line therapy rather than for acquired resistance, including introducing the ALEX trial that is trying to answer this question.
Please advice! I have UTI and 2 different organisms are detected and only macrodantine antibiotic is applicable for both. I am on Tarceva treatment at...
I had stage 1 lung cancer. Had lobectomy 11 weeks ago. Removed bottom two lobes, right lung. No chemo needed. Taking Cymbalta for nerve pain and it...
My 79 yo uncle was just diagnosed with NSCLC Adenocarcinoma. Waiting for an oncologist appointment set for July 19th, in the meantime here is his PET...
If you struggling with depression or going thru a tuff time in your life maybe trying to seek spiritual help would help you like it helped me...
My husband was recently dx'd with stage 4 lung ca due to metastatic pleural effusion, of which he has a permanent chest tube in place with approx 600...
Dr. Edward Garon warns that it is still too early to compare which immune therapies will be more effective in treating lung cancer.February 2014.
[powerpress]
Here's a text-heavy but still brief summary "slidedoc" of what I would consider to be the core principles of managing locally advanced, or stage III, non-small cell lung cancer (NSCLC). This is a heterogeneous population that accounts for about 40% of the patients newly diagnosed with NSCLC, with some having far more extensive and bulky disease than others. Though individual treatment recommendations should be made by the physicians directly reviewing the details of a patient's case, the key principles still govern the overall plan.
Dr. Cathy Pietanza of Memorial Sloan Kettering discusses whether PARP treatments can be taken alone or if they must be taken with other drugs. February 2014.
[powerpress]
(Old Thread request)
We've covered the question of maintenance therapy for lung cancer in many posts over the past 5-6 years as it has evolved from a concept with little evidence to a standard of care, but it is difficult to get a good summary of the big picture. This presentation is my attempt to distill the field into the most important principles.
Why would an ALK lung cancer patient need a repeat biopsy? The doctors discuss the need for and frequency of repeat biopsies.
Several new treatments for ALK positive lung cancer patients are on the horizon. In this video, the doctors discuss them while patients in the audience share some of their experiences with side effects on various treatments.
[powerpress]
(IE/Firefox Users: If you have playback problems, please view on YouTube or try the "Download" button above. Get the latest QuickTime Player.)
New treatments for ALK rearrangements are on the horizon. In this video, the doctors discuss how they determine whether or not they change treatments for their patients once they begin to show progression while on Xalkori (crizotinib).
[powerpress]
How often should ALK patients receive scans to determine if their disease has progressed in various parts of the body?
[powerpress]
(IE/Firefox Users: If you have playback problems, please view on YouTube or try the "Download" button above. Get the latest QuickTime Player.)
The doctors discuss how patients can navigate the tricky waters of stopping therapy while avoiding painful and sometimes life-threatening flare.
[powerpress]
(IE/Firefox Users: If you have playback problems, please view on YouTube or try the "Download" button above. Get the latest QuickTime Player.)
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.